Tali Nir
19 Papers
8 Citations
Tali Nir is an academic researcher. The author has contributed to research in topics: Melatonin & Medicine. The author has an hindex of 15, co-authored 19 publications.
Chat about Author
Papers
Prolonged‐release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects
TL;DR: PR‐melatonin is the first drug shown to significantly improve quality of sleep and morning alertness in primary insomnia patients aged 55’years and older, suggesting more restorative sleep, and without withdrawal symptoms upon discontinuation.
Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder
TL;DR: PedPRM was efficacious and safe for treatment of insomnia in children and adolescents with ASD with/without ADHD and NGD, and the acceptability of this pediatric formulation in a population who usually experience significant difficulties in swallowing was remarkably high.
251
Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.
TL;DR: PR-melatonin results in significant and clinically meaningful improvements in sleep quality, morning alertness, sleep onset latency and quality of life in primary insomnia patients aged 55 years and over.
239
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial
Alan G Wade,Mildred Farmer,Gil Harari,Naama Fund,Moshe Laudon,Tali Nir,Anat Frydman-Marom,Nava Zisapel +7 more
TL;DR: Add-on PRM has positive effects on cognitive functioning and sleep maintenance in AD patients compared with placebo, particularly in those with insomnia comorbidity, and the results suggest a possible causal link between poor sleep and cognitive decline.
Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety
TL;DR: The results demonstrate short- and long-term efficacy and safety of PRM in elderly insomnia patients and low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in insomnia.